AETHLON MEDICAL INC (AEMD): Nasdaq/NYSE listing notice — Aethlon Medical receives Nasdaq delisting notice for bid price below $1.00, requests hearing, implements reverse split

AETHLON MEDICAL INC

Received Nasdaq notice on Oct 16, 2025 for non-compliance with minimum bid price of $1.00 over 30 consecutive business days.
Company requested a hearing before Nasdaq Hearings Panel, automatically staying delisting pending decision.
Implemented 1-for-10 reverse stock split effective Oct 16, trading Oct 20, to regain compliance.
Stock continues to trade on Nasdaq Capital Market under symbol AEMD while hearing is pending.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

AETHLON MEDICAL INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

October 16, 2025, Aethlon Medical, Inc. (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock was below $1.00 per share for 30 consecutive business days, the Company was not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Marketplace Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) and subject to the compliance and de

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

AETHLON MEDICAL INC filing history →

Source: SEC EDGAR

accession 0001683168-25-007719

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.